Abstract
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Depsipeptides / chemistry
-
Depsipeptides / metabolism
-
Depsipeptides / therapeutic use
-
Histone Deacetylase Inhibitors / chemistry*
-
Histone Deacetylase Inhibitors / metabolism
-
Histone Deacetylase Inhibitors / therapeutic use
-
Histone Deacetylases / chemistry*
-
Histone Deacetylases / metabolism
-
Humans
-
Hydroxamic Acids / chemistry
-
Hydroxamic Acids / metabolism
-
Hydroxamic Acids / therapeutic use
-
Neoplasms / drug therapy
-
Patents as Topic
-
Protein Binding
-
Sulfonamides / chemistry
-
Sulfonamides / metabolism
-
Sulfonamides / therapeutic use
-
Vorinostat
Substances
-
Depsipeptides
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Sulfonamides
-
Vorinostat
-
romidepsin
-
Histone Deacetylases
-
belinostat